Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
Open Access
- 1 January 2009
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 113 (1), 18-27
- https://doi.org/10.1182/blood-2008-06-165654
Abstract
Eighteen relapsed patients with measurable indolent non-Hodgkin lymphoma (NHL) were vaccinated with dendritic cells (DCs) loaded with killed autologous tumor cells. Six patients had objective clinical responses including 3 continuous complete responses (CRs) and 3 partial responses (PRs), with a median follow up of 50.5 months. Eight patients had stable disease, whereas 4 had progressive disease. Clinical responses were significantly associated with a reduction in CD4+CD25+FOXP3+ regulatory T cells, an increase in CD3−CD56dimCD16+ natural killer (NK) cells, and maturation of lymphocytes to the effector memory stage in either postvaccination peripheral blood or tumor specimen samples. In partial responding patients, vaccination significantly boosted the IFN-γ–producing T-cell response to autologous tumor challenge. In one HLA-A*0201+ patient who achieved CR, IL-4 release by circulating T cells in response to tumor-specific IgH-encoded peptides was also documented. Immunohistochemical analysis of tumor biopsies using biotin-conjugated autologous serum samples revealed a tumor-restricted humoral response only in the postvaccination serum from responding patients. Collectively these results demonstrate that vaccination with tumor-loaded DCs may induce both T- and B-cell responses and produces clinical benefits in indolent NHL patients with measurable disease. This study is registered with the Istituto Superiore di Sanità: http://www.iss.it with protocol number 7578-PRE 21-801.This publication has 44 references indexed in Scilit:
- Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trialsBritish Journal of Haematology, 2008
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphomaBlood, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Experience with heat shock protein‐peptide complex 96 vaccine therapy in patients with indolent non‐Hodgkin lymphomaCancer, 2006
- Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular LymphomaJNCI Journal of the National Cancer Institute, 2006
- Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine★Breast Cancer Research and Treatment, 2006
- Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemiaLeukemia, 2005
- Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell VaccinationClinical Cancer Research, 2004
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasThe New England Journal of Medicine, 1984